HOME >> BIOLOGY >> NEWS
Researchers test new therapy for advanced melanoma

Tampa, FL (March, 25, 2005) --Melanoma is a particularly deadly form of skin cancer very resistant to treatment. Researchers at H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida are testing a promising new therapy that prompts the immune system to aid in the fight against melanoma tumors.

"This is a milestone clinical trial because it is the first time that electroporation is being used to deliver plasmid DNA in a gene therapy study in humans," said Richard Heller, PhD, USF professor of medical microbiology and immunology who helped develop the technology used in the study.

Electroporation is a technique in which a hand-held device applied to the skin delivers pulses of electricity to open up pores in the tumor cell membrane. This opening allows a small therapeutic molecule -- in this case a molecule known as a DNA plasmid that contains the gene for Interleukin-12 -- to slip inside the melanoma tumor before the membrane reseals.

"Melanoma does not respond well to standard chemotherapy," said Adil Daud, MD, assistant professor of oncology in the Cutaneous Oncology Program at Moffitt. "Gene therapy gives us the flexibility to introduce a huge variety of potential targets for treatment, but its major limitation has been getting the gene into the cancer. If electroporation can deliver the gene to these tumors reliably and without serious side effects, melanoma and other cancers would be open to many new treatment possibilities."

Six years of laboratory studies by Dr. Heller and his colleagues preceded the initial human trial begun earlier this year at Moffitt. The collaboration of USF and Moffitt in this trial is a good example of translational research -- moving the new application of a gene transfer technology from an animal model to the patient. Dr. Heller's team worked extensively with Dr. Daud to adapt the electroporation technique used on mice to humans.

The researchers injected the
'"/>

Contact: Anne DeLotto Baier
abaier@hsc.usf.edu
813-974-3300
University of South Florida Health
5-Apr-2005


Page: 1 2

Related biology news :

1. Researchers find pathway that controls cell size and division
2. Researchers watch antibiotics, bacteria meet at atomic level
3. Researchers discover gene responsible for Restless Legs Syndrome
4. Researchers witness natural selection at work in dramatic comeback of male butterflies
5. Researchers discover human embryonic stem cells are the ultimate perpetual fuel cell
6. Researchers use new approach to predict protein function
7. Researchers probe risks, benefits of folic acid fortification
8. Researchers identify genetic mutation that may alter tumor cell proliferation
9. Researchers discover method for identifying how cancer evades the immune system
10. Researchers use adult stem cells to create soft tissue
11. Researchers find gene that spurs development of the epididymis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Researchers test new therapy for advanced melanoma

(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/9/2015)... Feb. 9, 2015  Lintec of America recently announced ... carbon nanotube (CNT) macrostructures, including sheets, yarns and ribbons, ... Leveraging the vast industrial resources of the ... , Lintec of America is forming the Nano-Science ... , focusing on scaling up the manufacturing and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
(Date:3/4/2015)... , March 4, 2015  BioClinica®, Inc., ... technology provider, today announced that clinical trial ... convened at its annual European User Conference ... to discuss the use of its eClinical ... eClinical technologies include: the Microsoft Office-Smart OnPoint ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
(Date:3/4/2015)... 4, 2015 Lancée ... Paris en décembre 2011, l,étude collaborative ... », qui compare   l es microsphères ... sorafénib dans le carcinome hépatocellulaire avancé, a recruté ... foie avancé   ; les résultats sont attendus ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
Cached News: